Avidity Biosciences Inc (NASDAQ: RNA) is 9.08% higher on its value in year-to-date trading and has touched a low of $21.56 and a high of $56.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RNA stock was last observed hovering at around $30.48 in the last trading session, with the day’s gains setting it 1.24%.
Currently trading at $31.72, the stock is 3.63% and 2.05% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.17 million and changing 4.07% at the moment leaves the stock -18.23% off its SMA200. RNA registered 29.89% gain for a year compared to 6-month loss of -24.02%. The firm has a 50-day simple moving average (SMA 50) of $31.0842 and a 200-day simple moving average (SMA200) of $38.791576.
The stock witnessed a -0.88% gain in the last 1 month and extending the period to 3 months gives it a -2.37%, and is -2.73% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.17% over the week and 7.07% over the month.
Avidity Biosciences Inc (RNA) has around 391 employees, a market worth around $3.81B and $10.90M in sales. Profit margin for the company is -2957.72%. Distance from 52-week low is 47.12% and -43.36% from its 52-week high. The company has generated returns on investments over the last 12 months (-22.57%).
The EPS is expected to shrink by -32.24% this year
328.0 institutions hold shares in Avidity Biosciences Inc (RNA), with institutional investors hold 112.95% of the company’s shares. The shares outstanding are 119.89M, and float is at 111.07M with Short Float at 15.26%. Institutions hold 107.31% of the Float.
The top institutional shareholder in the company is FMR LLC with over 16.16 million shares valued at $$660.1 million. The investor’s holdings represent 18.5285 of the RNA Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 10.92 million shares valued at $$445.94 million to account for 12.5173 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 8.62 million shares representing 9.8868 and valued at over $$352.23 million, while RTW INVESTMENTS, LP holds 8.2362 of the shares totaling 8.81 million with a market value of $$359.76 million.
Avidity Biosciences Inc (RNA) Insider Activity
The most recent transaction is an insider sale by Flanagan W. Michael, the company’s Chief Scientific Officer. SEC filings show that Flanagan W. Michael sold 20,000 shares of the company’s common stock on Mar 11 ’25 at a price of $30.13 per share for a total of $0.6 million. Following the sale, the insider now owns 91975.0 shares.
Still, SEC filings show that on Mar 03 ’25, Gallagher Kathleen P. (Chief Program Officer) disposed off 5,875 shares at an average price of $29.41 for $0.17 million. The insider now directly holds 50,554 shares of Avidity Biosciences Inc (RNA).
